BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its development of 2-bromo-LSD was highlighted in Carleton University’s articled titled “Beyond the Magic of Mushrooms: Using Psychedelic Derivatives to Treat Depression”. The article discusses the therapeutic potential of 2-bromo-LSD in treating depression. BetterLife’s BETR-001 is currently undergoing IND-enabling studies and projected to enter human trials in 2024.
Related news for (BETRF)
- BetterLife Pharma Provides Scientific Update on Neuroplastogenic Activity of BETR-001
- BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders
- BetterLife Pharma Appoints Corporate Advisor
- BetterLife Pharma Appoints New Director
- Amendment of Disclosures in Past Management Information Circulars